Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH). It preferentially inhibits denovo pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their proliferation, thereby suppresses both cell mediated and humoral immune responses. Clinical trials in kidney transplant recipients have shown the efficacy of MMF in reducing the incidence and severity of acute rejection episodes. It also improves long term graft function as well as graft and patient survival in kidney transplant recipients. MMF is useful as a component of toxicity sparing regimens to reduce or avoid exposure of steroids or calcineurin inhibitor (CNI). Enteric-coated mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in kidney transplant recipients with efficacy and safety profile similar to MMF. © 2009 Dalal et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Dalal, P., Grafals, M., Chhabra, D., & Gallon, L. (2009). Mycophenolate mofetil: Safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Therapeutics and Clinical Risk Management. https://doi.org/10.2147/tcrm.s3068
Mendeley helps you to discover research relevant for your work.